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We report the case of an old man treated with methylprednisolone for chronic lymphoid leukemia. After two months of treatment,
he declared an acute steroid psychosis and beat his wife to death. Steroids were stopped and the psychotic symptoms subsided, but
his condition declined very quickly. The clinical course was complicated by a major depressive disorder with suicidal ideas, due to
the steroid stoppage, the leukemia progressed, and by a sudden onset of a fatal pulmonary embolism. This clinical case highlights
the importance of early detection of steroid psychosis and proposes, should treatment not be stopped, a strategy of dose reduction
combined with a mood stabilizer or antipsychotic treatment. In addition have been revised the risks of the adverse psychiatric
eﬀects of steroids.
1.Introduction
Argentine physiologist Bernardo Houssay identiﬁed corti-
soneanddescribeditsmainactionsonthebodyatthebegin-
ning of the 20th century. In 1950, the three researchers Philip
Hench, Edward Kendall, and Tadeus Reichstein received the
Nobel Prize for physiology and medicine for “the isolation
of cortisone and the introduction of its clinical use” and
corticosteroids were commercialized. Within a year, initial
reports were received of their undesirable psychiatric eﬀects
[1, 2].
Cortisone is secreted by the adrenal cortex, under the
control of the hypothalamus, which is itself regulated by
the limbic system (tonsils, hippocampus) and the anterior
pituitary gland. The increase in the secretion of glucocorti-
coids follows an acute event deemed as stressful by the limbic
system (mobilization of energetic resources and inhibition of
auxiliary activities) [3].
Corticosteroid therapy is today a treatment which has
many broad uses, from autoimmune and system diseases
to severe inﬂammatory and allergic reactions, as well as in
palliative care and support [2, 4]. The counterweight of
thesebroadtherapeuticindicationsiswitnessedinnumerous
undesirable side eﬀects,including amongst others metabolic,
endocrine, digestive, immunological, ophthalmological, der-
matological, and neuropsychiatric disorders. Concerning
corticosteroid-induced adverse psychiatric eﬀects, the liter-
ature remains undeveloped from a pharmacoepidemiolog-
ical perspective and recent reviews principally consist on
summarizing published data based on case reports and case
series [5, 6]. However, links between HPA axis dysfunction
and psychosis, mood, or anxiety disorders were clearly
established [7]. An impairment in glucocorticoid receptors
function (glucocorticoid resistance) could be responsible
of their “depressogenic” eﬀect in patients with increased
levels of glucocorticoids like in Cushing’s syndrome or in
exogenous treatment with synthetic glucocorticoids [8, 9].
Corticosteroids are associated with changes in the temporal
lobe, detected by structural, functional, and spectroscopic
imaging [10]. As regards the undesirable neuropsychiatric
eﬀects, these aﬀect around 34% of patients with 6% of
patients experiencing severe reactions. Dosage is directly
related to the incidence of adverse eﬀects but is not
related to the timing, severity, or duration of these eﬀects
Corticosteroid-induced symptoms frequently occur during
the ﬁrst few weeks of therapy and typically resolve with
dosage reduction or discontinuation of corticosteroids [11].
No speciﬁc personality has been identiﬁed as a risk factor
for corticosteroid-induced psychosis episode. Moreover, it
is not possible to determine whether past psychiatry illness2 Case Reports in Medicine
disorder could be risk factors for the development of a
corticosteroid-induced psychiatric episode [12].
We report on the case of a patient who presented an
acute corticosteroid-induced psychotic reaction, resulting in
the committing of a heteroaggressive deed which led to the
death of his spouse.
2.CaseReport
We reported the case of a 77-year-old man, living with his
wife, who had four children: three daughters and a son.
He had never suﬀered from any previous psychiatric illness.
In April 2009, he was treated with pregabalin (450mg/day)
and codeine (120mg/day) shingles. At this moment, no
biological signs of immunodepression were found. After
15 days, he suddenly presented impairments in temporal
and attentional orientation, deﬁcits in consciousness and
memory, suggesting a confusional state [13]. The treatment
was stopped because of adverse eﬀects.
In June 2009, the patient complained on an important
fatigue and his general practitioner (GP) prescribed a blood
cells count, which was found around 28000/µL, with a
monoclonal proliferation of B cells. The chest radiography
highlighted a mediastinal adenopathy. The cerebral scanning
was normal, and the infectious blood tests were negative
for HIV and treponema. In July 2009, an internal physician
concluded to a chronic lymphoid leukemia and purposed a
treatment using methylprednisolone (80mg/day), and this
obtained a good response. After 22 days of treatment,
the blood count was normalized. However, the patient
complained of sleep disorders, such as sleep discontinuation,
early awakenings, temporal and spatial disorientation, and
mood dysregulation (euphoria). The ﬁrst of September,
when his neoplasia was stabilized, he called himself emer-
gency services and told them that “he made a mistake.”
At home, the rescuers found his wife laid down on the
ﬂoor, with several injuries, beaten to death. The patient,
dazed, walked around his wife. He spoke to himself with
incomprehensible words. It was impossible to communicate
with him. This disorganization, both the emotional state
and behavior or language, suggests psychotic symptoms.
The autopsy of the wife revealed: broken nose, broken
right elbow, broken left humerus, broken ribs, meningeal
hemorrhage, bilateral hemothorax, pulmonary contusions,
with much bruising and many contusions to the face, arms,
and legs.
The emergency services diagnosed an acute delirious
state (poisoning ideas, visual hallucinations), a dissociative
syndrome, and elements of confusion such as amnesia, dis-
orientation, and symptomatological ﬂuctuation. He needed
attention and was hospitalized without his consent. He was
disorientated and unable to remember what had happened.
For him, it was a contrivance, and he thought that his wife
was still alive. His reaction was very anxious and nervous.
Hyponatremia (126mmol/L) and community pneumonia
(by streptococcus pneumoniae) were also found. The brain
scanning was normal. His family reported potomania’s
tendencies that could explain the hyponatremia. He took
no treatment susceptible to interact with ADH. The steroids
were stopped, and delusional symptoms declined in 72
hours, after a treatment by loxapine (100mg, once daily).
Natremia was progressively corrected by serum [Na+]. He
realized what he had done and decided to refuse to live. He
felt feelings of guilt and shame. He progressed to a major
depressive disorder with suicidal ideas. Following steroid
stoppage, the leukemia progressed.
Onthe11thofSeptember,hepresentedrespiratoryinsuf-
ﬁciency and died consequently to a pulmonary embolism
on the 21st of September. An autopsy should be interesting
but was not asked by the judge. According to Naranjo’s algo-
rithm, the relationship between corticosteroid and adverse
eﬀects could be possible (total score +3) [14].
3. Discussion
This case is an example of the possible risk of iatrogenic
psychotic reactions in the occurrence of forensic acts. Several
arguments could be raised to support the link between taken
corticosteroids and the murderous behavior.
(i) The patient already displayed an iatrogenic reac-
tion in April 2009 following the implementation
of treatment using pregabalin and codeine-based
paracetamol for shingles in the lower back. His state
ofsecondaryconfusedagitationthenrapidlydeclined
following stoppage of treatment. As a preexisting
neurological disorder, we might suppose a sensibility
for this patient to iatrogenic eﬀects, but it is not
suﬃcient to clearly establish a relationship between
corticosteroids and forensic behaviour.
(ii) Previously, he never suﬀered from psychiatric symp-
toms requiring psychiatric consultation, hospitaliza-
tion, or speciﬁc drugs.
(iii) The symptoms were ﬂuctuating, appearing rapidly
after the start of treatment, composed of an acute
delusional syndrome with episodes of agitation and
disorientation linked to memory diﬃculties, atten-
tion deﬁcit, and an inversion of the day/night cycle.
No signs of dementia were found before the murder,
in particular by his GP.
(iv) Signiﬁcant sleep disorder without fatigue presented
just after the start of methylprednisolone were most
likely already signs of a corticosteroid-induced psy-
chiatric reaction [15].
The relationship between corticosteroids and murder is not
certaininourcase,butpossible.Otherfactorsarewellknown
to lead to a confusional syndrome such as hyponatremia and
infectiousstate.Asregardsthesepsis,weknowthatitappears
inanatypicalwayintheformofaconfusedsyndromein52%
of elderly subjects [16]. In our case, it could be advanced
that the pneumonia, due to the immunodepressed state,
which is itself due to the chronic lymphoid leukemia, added
to the hyponatremia, contributed to weakening cerebral
homeostasis,andthusfacilitatedtheoccurrenceofiatrogenic
eﬀects, such as cortico-induced psychosis.Case Reports in Medicine 3
That is why it is important to detect early steroid
psychosis and to propose, should treatment not be stopped,
astrategyofdose reductioncombinedwithamoodstabilizer
or antipsychotic treatment, for example, haloperidol or
chlorpromazine. Olanzapine and risperidone appear limited
to subacute cases. Theoretically, lithium could be used as
prophylaxis for corticosteroid-induced psychosis with bene-
ﬁcial eﬀects. But, in clinical practice, corticosteroids-induced
changes in sodium balance might increase the risk of lithium
intoxication and renal dysfunction. Other mood stabilizers
have been tested like carbamazepine, which decrease serum
concentration of prednisolone, or valproate, but they are
not suﬃciently documented to be recommended. A decline
in declarative and working memory is also reported during
corticosteroid therapy. Lamotrigine and memantine have
beenshowntoreverse,atleastpartially,thedeclarativemem-
ory eﬀects of corticosteroids [10]. Some studies reported
beneﬁcial eﬀects of serotonin reuptake inhibitor but also
less documented. Dosage had to be ascertained case by case.
Speed of improvement is very inconstant. However, most of
the patients improved in the ﬁrst three days with a tail-oﬀ
period to bring recovery. Disease management strategies are
insuﬃciently documented to be recommended [17–19].
Reckart and Eisendrath showed that over 80% of patients
undergoing corticosteroid therapy recruited to their study
had not been informed of the risks of the occurrence of
psychiatric side eﬀects, while 50% of patients complained of
various symptoms (insomnia, euphoria, confusion, memory
diﬃculties, depressive symptoms) and, in 62% of cases, they
had not informed the prescribing party of the occurrence
of these side eﬀects [20]. It seems diﬃcult to bridge the
gap in terms of information about the psychiatric side
eﬀects of corticosteroids, due both to their frequency and
their potential seriousness, as this clinical situation shows.
I n f o r m a t i o na b o u tc o m m o ns i d ee ﬀects such as a change in
mood must be systematically given to the patient and those
around him/her. It may be supposed that once informed of
these possible iatrogenic eﬀects, the patient will pay more
attention and report any symptoms early should they occur,
whichmayinsomesituationspreventanevolutionintomore
serious diﬃculties, such as corticosteroid-induced psychosis.
Moreover,anyphysicianmusthavespeciﬁcrelationshipsalso
with caregivers who may be their ﬁrst to become aware of the
adverse psychological eﬀects of the drug.
4. Conclusion
This clinical illustration underlines the importance of bear-
ing in mind the possible occurrence of serious psychiatric
side eﬀects due to corticosteroids, even if these are excep-
tional in nature. The extremely acute onset of symptoms, the
onset of delusions, a history of neuropsychiatric iatrogenic
disorder, the existence of somatic precipitating disorders,
and confusion factors should always alert clinicians to said
possibility. The patient and those surrounding him/her must
be made aware of the risks of adverse psychiatric side eﬀects
of steroids, for both ethical and forensic reasons, and these
should be reported as soon as possible to the clinician should
they occur.
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